- Question
- Does once-weekly semaglutide improve symptoms, physical limitations and body weight in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes?
- Design
- Phase 3, randomized, double-blind (quadruple masking), placebo-controlled trial with 616 participants randomized and 52 weeks of treatment.
- Population
- Patients with heart failure with preserved ejection fraction, a body-mass index of 30 or more, and type 2 diabetes.
- Intervention
- Semaglutide 2.4 mg subcutaneously once weekly for 52 weeks.
- Control
- Semaglutide-matching placebo once weekly for 52 weeks.
- Primary outcome
- Two primary end points: change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS, range 0 to 100, higher scores indicating fewer symptoms) and change in body weight.
- Results
- The KCCQ-CSS increased by 13.7 points with semaglutide and 6.4 with placebo (estimated difference 7.3 points; 95% CI 4.1 to 10.4; P<0.001), and body weight changed by -9.8% versus -3.4% (difference -6.4 percentage points; 95% CI -7.6 to -5.2; P<0.001). The difference in 6-minute walk distance was 14.3 m (95% CI 3.7 to 24.9; P = 0.008).
- Safety
- Serious adverse events were less frequent with semaglutide (55 participants, 17.7%) than with placebo (88 participants, 28.8%).
- Conclusion
- In patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide reduced symptoms and physical limitations more and produced greater weight loss than placebo at 1 year.
- Why it matters
- It provided evidence for a therapy targeting obesity-related heart failure with preserved ejection fraction in people with type 2 diabetes, a population with a high symptom burden and few specific treatment options.
Card generated automatically with AI from the abstract of the original publication and the trial registry; every figure was checked against those sources. It may contain errors: verify the data at the source before using it for clinical decisions.
Generated on October 14, 2026